{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"20-29 years"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"30-39 years"},{"measurements":[{"groupId":"OG000","value":"17"}],"title":"40-49 years"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"50-59 years"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"60-69 years"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"OG000","title":"Bevacizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Age at Enrollment","type":"SECONDARY","unitOfMeasure":"Participants"}